Mechanism and Management of Checkpoint Inhibitor-Related Toxicities in Genitourinary Cancers

SIMPLE SUMMARY: Immune therapy using checkpoint inhibitors has been increasing in genitourinary cancers for the past decade, starting with monotherapy in renal cell carcinoma and urothelial carcinoma to now include many first-line combinations. More combinations and FDA/EMA indications are undoubted...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Haoran, Sahu, Kamal K., Maughan, Benjamin L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139183/
https://www.ncbi.nlm.nih.gov/pubmed/35626064
http://dx.doi.org/10.3390/cancers14102460

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139183/
https://www.ncbi.nlm.nih.gov/pubmed/35626064
http://dx.doi.org/10.3390/cancers14102460

Ejemplares similares